首页 / 院系成果 / 成果详情页

Risk of HIV Viral Rebound in the Era of Universal Treatment in a Multicenter Sample of Persons With HIV in Primary Care 期刊论文

编号：

733DFD853D2E10F9E676FFB9895B2544
作者：

Liu, Tao^[1];Chambers, Laura C.^[2];Hansen, Blake^[1];Bazerman, Lauri B.^[2];Cachay, Edward R.^[3];Christopoulos, Katerina^[4];Drainoni, MariLynn^[5,6];Gillani, Fizza S.^[7];Mayer, Kenneth H.^[8,9]Moore, Richard D.^[10]Rana, Aadia^[11];Beckwith, Curt G.^[2,7,12];
语种：

英文
期刊：

OPEN FORUM INFECTIOUS DISEASES ISSN：2328-8957 2023 年 10 卷 6 期 ; JUN 1
疾病分类：

艾滋病
关键词：

HIV antiretroviral therapy long-term suppression viral rebound virologic failure
摘要：

Among persons with HIV who have sustained viral suppression on antiretroviral treatment, the majority will continue to have viral suppression over a two-year period. Some patients may benefit from treatment adherence supports. Background Antiretroviral therapy (ART) is recommended for people with HIV (PWH), irrespective of CD4 cell count, to improve their health and reduce the risk of transmission to sexual partners through long-term viral suppression. We identified risk factors for viral rebound among patients with a period of stable viral suppression to inform counseling and monitoring. Methods We conducted a multisite, retrospective study of PWH with a 2-year period of sustained viral suppression in the United States using the Centers for AIDS Research Network of Integrated Clinical Systems cohort. We used multivariable logistic regression to identify characteristics independently associated with any viral rebound (viral load [VL] & GE;200 copies/mL) and sustained viral rebound (VL & GE;200 copies/mL followed by a VL that was also & GE;200 copies/mL within 6 months), within 2 years of follow-up. Results Among 3496 eligible patients with a 2-year period of sustained viral suppression, most (90%) continued to have viral suppression over 2 additional years; 10% experienced viral rebound, and 4% experienced sustained viral rebound. In multivariable analyses, Black race, current smoking, integrase strand transfer inhibitor use, and 5- to 9-year duration of ART were positively associated, and being age & GE;50 years was negatively associated, with any viral rebound. Only current smoking and 5- to 9-year (vs 2- to 4-year) duration of ART were positively associated, and being age & GE;60 years was negatively associated, with sustained viral rebound. Conclusions Most people retained in clinical care and with HIV viral suppression on ART will have persistent viral suppression. However, some patients may benefit from additional treatment adherence support.
推荐引用方式
GB/T 7714：

Liu Tao,Chambers Laura C.,Hansen Blake, et al. Risk of HIV Viral Rebound in the Era of Universal Treatment in a Multicenter Sample of Persons With HIV in Primary Care [J].OPEN FORUM INFECTIOUS DISEASES,2023,10(6).
APA：

Liu Tao,Chambers Laura C.,Hansen Blake,Bazerman Lauri B.,&Beckwith Curt G..(2023).Risk of HIV Viral Rebound in the Era of Universal Treatment in a Multicenter Sample of Persons With HIV in Primary Care .OPEN FORUM INFECTIOUS DISEASES,10(6).
MLA：

Liu Tao, et al. "Risk of HIV Viral Rebound in the Era of Universal Treatment in a Multicenter Sample of Persons With HIV in Primary Care" .OPEN FORUM INFECTIOUS DISEASES 10,6(2023).
数据来源自科睿唯安Web of Science核心合集
入库时间：

2023/10/16 10:38:54
更新时间：

2023/10/16 10:38:54

浏览次数：22  下载次数：0

分享到：

浏览次数：22

下载次数：0

打印次数：0